Biggest News Aggregation in the World
📰 Pharma Exec News

Pharma Exec News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Pharma Exec. Real-time updates on events, politics, business and more.

Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd's Approval of Oteseconazole Capsules for the Treatment of Severe Vulvovaginal Candidiasis (VVC) in China

/PRNewswire/ -- Mycovia Pharmaceuticals, Inc. ("Mycovia"), an emerging biopharmaceutical company, today announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd...
Hong Kong Vulvovaginal Candidiasis Hengrui Pharma Drug Administration National Medical Products Administration For Oteseconazole Capsules Jiangsu Hengrui Pharmaceuticals Co Ltd

Camrelizumab in Combination with Rivoceranib (Apatinib) Significantly Prolonged Overall Survival and Progression-Free Survival vs. Sorafenib in Patients with Unresectable Hepatocellular Carcinoma in a Multinational Phase 3 Trial, a Joint Program with Elev | Antibodies

Camrelizumab in Combination with Rivoceranib (Apatinib) Significantly Prolonged Overall Survival and Progression-Free Survival vs. Sorafenib in Patients with Unresectable Hepatocellular Carcinoma in a Multinational Phase 3 Trial, a Joint Program with Elevar Therapeutics
France General South Korea Republic Of Korea Rivoceranib Apatinib Hengrui Pharma Elevar Therapeutics Inc

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China

/PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization...
Lianshan Zhang Hengrui Pharma Frank Jiang Jiangsu Hengrui Pharmaceuticals Cstone Pharmaceuticals Jiangsu Hengrui Pharmaceuticals Co Ltd

CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China

/PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization...
Lianshan Zhang Hengrui Pharma Frank Jiang Jiangsu Hengrui Pharmaceuticals Cstone Pharmaceuticals Jiangsu Hengrui Pharmaceuticals Co Ltd

CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China

SUZHOU, China, Nov. 21, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of
Lianshan Zhang Hengrui Pharma Frank Jiang Jiangsu Hengrui Pharmaceuticals Cstone Pharmaceuticals Prnewswire Cstone Pharmaceuticals

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science